Drug Profile
iC9/CAR.19/IL15-transduced CB-NK cells
Alternative Names: iC9/CAR.19/IL15-transduced cord blood-NK cells; NK-cells-MD-Anderson-Cancer-Center/Bellicum-PharmaceuticalsLatest Information Update: 05 Apr 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Haematological malignancies
Most Recent Events
- 23 Feb 2024 Discontinued - Phase-I/II for Haematological malignancies (Second-line therapy or greater) in USA (IV) before February 2024 as Bellicum Pharmaceuticals has winded down its business and no longer active
- 26 Oct 2023 iC9/CAR.19/IL15-transduced CB-NK cells is still in phase I/II trials for Haematological malignancies (Second-line therapy or greater) in USA (IV) (NCT03056339)
- 23 Oct 2023 UNC Lineberger Comprehensive Cancer Center and Bellicum Pharmaceuticals plans a phase I/II trial for Head and neck squamous cell carcinoma (Second-line therapy or greater) in USA in December 2023 (NCT06096038)